Chronic Disease Management with USA’s Biofourmis

CDC estimates that 6 in 10 American adults have 1 chronic disease whereas 4 in 10 suffer from 2 or more chronic diseases. Learn how Biofourmis is changing this.

CDC estimates that 6 in 10 American adults have 1 chronic disease whereas 4 in 10 suffer from 2 or more chronic diseases. Chronic diseases, which include conditions like heart disease, stroke, diabetes and cancer, are so common in the U.S. that they drive a significant portion of the nation's healthcare costs. 

To treat such an extensive problem Biofourmis was founded by Kuldeep Singh Rajput and co-founded by Mark Niu and Maulik Majumda. They believe in providing personalized, predictive care for better outcomes. For this, they use advanced technology to improve the delivery of healthcare outside the hospital. The Boston-based company develops software to “augment” patient care and optimizes the delivery of virtual health. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers.

The venture has 2 subsets - Biofourmis Therapeutics and Biofourmis Health. For the former, pharmaceutical companies prescribe Biofourmis’ digital therapeutics for better managing chronic conditions. It follows ‘beyond the pill’ model. The latter is an AI-based remote monitoring system that helps clinicians remotely monitor patients and thereby improve patient outcomes. It follows ‘home hospital’ model. Biofourmis 

BiovitalsHF, a platform designed for heart failure medication monitoring received an FDA breakthrough device designation last year. BiovitalsHF is supposed to streamline the titration process once patients leave hospitals by collecting and analyzing data from a wearable device.

They have raised a total of $143.6 million in funding over 8 rounds. The venture has been invested by SG Innovate, MassMutual, Openspace Ventures, SpesNet, Sequoia, SoftBank and EDBI. In addition, Biofourmis will use the funding for developing, validating and commercializing several released and unreleased digital therapeutics solutions across cardiology, respiratory, oncology and pain, with a focus on the United States and key Asian markets, including the Asia Pacific, China and Japan.

Their health partners are NOVARTIS, Mayo Clinic, AstraZeneca, SingHealth, Mundipharma and more. Their 2 acquisitions are wearable biosensor leader Biovotion and Takeda Pharmaceuticals oncology-focused digital therapeutics company Gaido Health. Since COVID remote monitoring and digital therapeutics has gained momentum. Will ventures like Biofourmis make this more the forefront of medicine in the future too?

Tags : #Biofourmis #KuldeepSinghRajput #MarkNiu #MaulikMajumda #BiofourmisTherapeutics #BiofourmisHealth #chronicdisease #remotepatientmonitoring #USA-startup #MediSpeak #smitakumar #medicircle

About the Author


Priyal Shah

Priyal Shah is a graduate of Media from Mithibai College, Mumbai. She is a writer, researcher and avid reader.

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Parental tips for keeping teens safe onlineFebruary 08, 2023
The Symptoms and Causes of Anorexia NervosaFebruary 08, 2023
Pervez Musharraf President of Pakistan died of Amyloidosis, a rare diseaseFebruary 07, 2023
National AIDS Control Program – Importance of knowing HIV statusFebruary 06, 2023
FGM : Let's End the practice that hurts girls and womenFebruary 06, 2023
World Cancer Day - Most prominent cancers of IndiaFebruary 04, 2023
World Cancer Day - Never Give up the HopeFebruary 04, 2023
Salt - Effects of Consuming too much SaltFebruary 03, 2023
India’s mission of eliminating dog-mediated rabies by 2030February 03, 2023
Climate change and healthFebruary 02, 2023
Rheumatoid Arthritis Awareness Day: Let's Create AwarenessFebruary 02, 2023
Importance of early diagnosis and cancer screeningFebruary 01, 2023
Union Budget 2023-2024: What's for Healthcare?February 01, 2023
Nourish You has raised $2million to Invest in R&D and Strengthen its Market Presence.February 01, 2023
Enzene Biosciences has raised $50million to expand in its core market of India and US.January 31, 2023
Enzene Biosciences has raised $50million to expand in its core market of India and US.January 31, 2023
World Leprosy Day 2023 – Act now, End LeprosyJanuary 30, 2023
The Warrior Expedition 32/26: A Mission to Encourage Youths to join Indian ForcesJanuary 30, 2023
Mental health – What’s normal and what’s abnormalJanuary 30, 2023
Big Data in Healthcare and Its BenefitsJanuary 27, 2023